Next Article in Journal
Newborn Screening Long Term Follow-Up in the Medical Home
Previous Article in Journal
Psychological Impact on Parents of an Inconclusive Diagnosis Following Newborn Bloodspot Screening for Cystic Fibrosis: A Qualitative Study
Version is current.
Open AccessArticle

Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy

1
Division of Inherited Metabolic Diseases, Regional Center for Expanded Neonatal Screening, Department of Women and Children’s Health, University Hospital of Padova, Via Orus 2/B, 35129 Padova, Italy
2
Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Via Ugo La Malfa, 153-90146 Palermo, Italy
3
Clinical Genetics Unit, Department of Women’s and Children’s Health, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
4
IRP Città della Speranza, Corso Stati Uniti 4, 35129 Padova, Italy
5
Neurological Unit, St. Bassiano Hospital, Via dei Lotti 40, 36061 Bassano del Grappa, Italy
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2019, 5(2), 24; https://doi.org/10.3390/ijns5020024
Received: 9 April 2019 / Revised: 17 June 2019 / Accepted: 18 June 2019 / Published: 21 June 2019
The increasing availability of treatments and the importance of early intervention have stimulated interest in newborn screening for lysosomal storage diseases. Since 2015, 112,446 newborns in North Eastern Italy have been screened for four lysosomal disorders—mucopolysaccharidosis type I and Pompe, Fabry and Gaucher diseases—using a multiplexed tandem mass spectrometry (MS/MS) assay system. We recalled 138 neonates (0.12%) for collection of a second dried blood spot. Low activity was confirmed in 62 (0.06%), who underwent confirmatory testing. Twenty-five neonates (0.02%) were true positive: eight with Pompe disease; seven with Gaucher disease; eight with Fabry disease; and two with Mucopolysaccharidosis type I. The combined incidence of the four disorders was 1 in 4497 births. Except for Pompe disease, a second-tier test was implemented. We conclude that newborn screening for multiple lysosomal storage diseases combined with a second-tier test can largely eliminate false-positives and achieve rapid diagnosis. View Full-Text
Keywords: lysosomal expanded newborn screening; Pompe disease; Fabry disease; Gaucher disease; MPS I; biomarkers; second-tier test; GAGs; lysoGb1; lysoGb3 lysosomal expanded newborn screening; Pompe disease; Fabry disease; Gaucher disease; MPS I; biomarkers; second-tier test; GAGs; lysoGb1; lysoGb3
Show Figures

Figure 1

MDPI and ACS Style

Burlina, A.B.; Polo, G.; Rubert, L.; Gueraldi, D.; Cazzorla, C.; Duro, G.; Salviati, L.; Burlina, A.P. Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy. Int. J. Neonatal Screen. 2019, 5, 24.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop